CIP
ZYNE

Chartwell Investment Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Chartwell Investment Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-90,378
Closed -$1.53M – 445
2017
Q2 		$1.53M Buy
90,378
+14,978
+20% +$298K 0.06% 322
2017
Q1 		$1.52M Buy
+75,400
New +$1.5M 0.06% 317

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Chartwell Investment Partners's ZYNE Position: Q3 2017 in Review

Chartwell Investment Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2017, closing a stake of 90,378 shares — an estimated $1.53M sold.

Chartwell Investment Partners first reported a position in ZYNE in Q1 2017 and held it in 2 quarters. The position peaked at $1.53M in Q2 2017. 67 funds tracked by Wall St. Rank hold ZYNE as of Q3 2017.

  • Chartwell Investment Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2017 after selling out during the quarter.
  • Chartwell Investment Partners sold 90,378 Zynerba Pharmaceuticals, Inc shares in Q3 2017, an estimated $1.53M.
  • Chartwell Investment Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 2 quarters.
  • Chartwell Investment Partners's Zynerba Pharmaceuticals, Inc position peaked at $1.53M in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2017.

Based on Chartwell Investment Partners's 13F filing for Q3 2017, filed 8 Nov 2017.